1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Asthma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016


DelveInsight’s Report, “Chronic Asthma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Chronic Asthma Report is to understand the market and pipeline status of the drugs around the Chronic Asthma to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Chronic Asthma. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Chronic Asthma.
- A review of the marketed products under prescription for Chronic Asthma, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Chronic Asthma with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Chronic Asthma drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Chronic Asthma drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Chronic Asthma drugs.
- Coverage of Chronic Asthma Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Chronic Asthma key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Chronic Asthma.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Chronic Asthma.
- API intelligence over marketed drugs forChronic Asthmaand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Chronic Asthma.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Chronic Asthma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Illustrative Table of contents
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Chronic Asthma
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Chronic Asthma
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Chronic Asthma
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables

- Chronic Asthma Therapeutic Market, US, Marketed Drugs by Application Type, 2016
- Chronic Asthma Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
- Chronic Asthma Therapeutic Market, US, (Year), 2016
- Chronic Asthma Marketed Drugs, API Manufacturers by US DMF Status, 2016
- Chronic Asthma Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Chronic Asthma Drugs, API Manufacturers, Europe by Country, 2016
- Chronic Asthma Drugs, API Manufacturers, India by State, 2016
- Chronic Asthma Drugs, API Manufacturers, China by Province, 2016
- Chronic Asthma Drugs, API Manufacturers by Geography 2016
- Chronic Asthma Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Chronic Asthma Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2016
- Phase III Drugs for Chronic Asthma, 2016
- Discontinued Drugs for Chronic Asthma, 2016

List of Figures

- Chronic Asthma Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
- Chronic Asthma Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
- Chronic Asthma Therapeutic Market, US, (Year), 2016
- Chronic Asthma Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
- Chronic Asthma Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Chronic Asthma Drugs, API Manufacturers, Europe by Country, 2016
- Chronic Asthma Drugs, API Manufacturers, India by State, 2016
- Chronic Asthma Drugs, API Manufacturers, China by Province, 2016
- Chronic Asthma Drugs, API Manufacturers by Geography 2016
- Chronic Asthma Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Chronic Asthma Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Asthma and COPD Drugs Market - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Asthma and COPD Drugs Market - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

U.S. and China Asthma and COPD Drugs Market: Overview Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell ...

Asthma - Market Insights, Epidemiology and Market Forecast-2023

Asthma - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Asthma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.